Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2000
11/28/2000US6153405 Nucleic acid which encodes a leader sequence from nisin and/or subtilin and a lantibiotic; for recombinant production of antibiotics
11/28/2000US6153402 Death domain containing receptors
11/28/2000US6153396 Drug screening by adding compound to mixture of chaperone and pilus subunit and determining the change in binding; bactericides for urinary tract infections
11/28/2000US6153378 Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
11/28/2000US6153226 Viricidal composition comprising a synergistic mixture of a phenol component and propolis; the phenol is a mono- or polyhydroxylated compound comprising a nonfused or fused benzene ring
11/28/2000US6153220 Taste-masked formulations
11/28/2000US6153217 Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
11/28/2000US6153210 Use of locally delivered metal ions for treatment of periodontal disease
11/28/2000US6153202 In ovo methods for utilizing live Edwardsiella ictaluri against enteric septicemia in channel catfish
11/28/2000US6153201 Oral immunization with papillomavirus virus-like particles
11/28/2000US6153193 Compositions for targeting biological agents
11/28/2000CA2308259A1 Method for assaying the function of flaa1 and wbpm
11/28/2000CA2305716A1 Method for assay of wbpm
11/28/2000CA2192820C Pyrazolo and pyrrolopyridines
11/28/2000CA2068943C 1,3-oxathiolanes useful in the treatment of hepatitis
11/28/2000CA2016500C Process for producing beta-lactamase inhibitor
11/27/2000CA2310218A1 A composition and method for treating bacterial infection
11/23/2000WO2000070099A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000WO2000070091A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION
11/23/2000WO2000070086A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
11/23/2000WO2000070060A1 Production of complex carbohydrates
11/23/2000WO2000070051A1 NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
11/23/2000WO2000070049A2 Extracellular signaling molecules
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070043A1 Recombinant human mannan-binding lectin
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000070020A1 Bacteria strain lactobacillus acidophilus n.v. ep 317/402 «narine» aaa used in the production of preparations and of dietetic, therapeutic and prophylactic products for treating dysbacteriosis and the consequences thereof
11/23/2000WO2000070017A2 Methods using of fab i and compounds modulating fab i activity
11/23/2000WO2000069913A1 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
11/23/2000WO2000069902A1 Long lasting fusion peptide inhibitors or viral infection
11/23/2000WO2000069895A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/23/2000WO2000069894A2 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
11/23/2000WO2000069891A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000WO2000069888A1 Self-assembling biomolecular structures
11/23/2000WO2000069884A2 Compositions isolated from skin cells and methods for their use
11/23/2000WO2000069877A1 4'-c-ethynyl purine nucleosides
11/23/2000WO2000069876A1 4'-c-ethynyl pyrimidine nucleosides
11/23/2000WO2000069875A1 C-2 modified erythromycin derivatives
11/23/2000WO2000069874A1 Novel crystalline forms of a macrolide antibiotic
11/23/2000WO2000069868A1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof
11/23/2000WO2000069862A2 Hemisynthetic method and intermediates thereof
11/23/2000WO2000069860A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069819A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000WO2000069818A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE sPLA2 INHIBITOR
11/23/2000WO2000069684A1 Drive system
11/23/2000WO2000069515A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000WO2000069470A2 Improved cellular uptake of bioactive agents
11/23/2000WO2000069462A1 Human monoclonal antibody
11/23/2000WO2000069456A2 Adjuvant combination formulations
11/23/2000WO2000069455A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
11/23/2000WO2000069428A2 Anionic polymers as toxin binders and antibacterial agents
11/23/2000WO2000069415A2 Melt granulation
11/23/2000WO2000069391A2 CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L11/GTPASE ACTIVATING REGION rRNA AND USES THEREOF
11/23/2000WO2000069277A1 A composition containing carvacrol and thymol for use as a bactericide
11/23/2000WO2000069269A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000WO2000069267A1 Microbially resistant compositions
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000040589A3 Novel derivatives from the class of oleandomycin
11/23/2000WO2000034237A3 Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
11/23/2000WO2000031242A3 Engineered cytotoxic ribonuclease
11/23/2000WO2000027430A3 Composition consisting of influenza virus surface proteins and dispensing device
11/23/2000WO2000027429A3 Vaccine against papillomatous digital dermatitis (pdd)
11/23/2000WO2000023053A3 Artificial antigen-specific cells and related methods
11/23/2000WO2000018355A3 Use of purified invaplex from gram negative bacteria as a vaccine
11/23/2000WO2000016764A3 Pharmaceutical compositions comprising derivatives of sulphur acids
11/23/2000WO2000016746A3 Immunogenic liposome compositions
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO2000002523A3 Vaccine against staphylococcus intoxication
11/23/2000WO1999065871A3 Thiolesters and uses thereof
11/23/2000CA2767116A1 Adjuvant combination formulations
11/23/2000CA2376722A1 Chloramphenicol biosynthetic pathway and gene cluster characterization
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374235A1 Production of complex carbohydrates
11/23/2000CA2374108A1 Anionic polymers as toxin binders and antibacterial agents
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2373824A1 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373486A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000CA2373485A1 Microbially resistant compositions
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372919A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372435A1 Recombinant human mannan-binding lectin
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372338A1 Long lasting fusion peptide inhibitors of viral infection
1 ... 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 ... 1798